Gary Horowitz has done deals in two unusual venues for Barr Pharmaceuticals Inc. Last month, the Simpson Thacher & Bartlett LLP partner represented Barr on its sale to Israeli generic drug manufacturer Teva Pharmaceutical Industries Ltd. for $9.8 billion in cash, stock and assumed debt. The deal was announced July 18. In 2006 Horowitz handled Barr's $2.5 billion acquisition of Croatian drugmaker Pliva d.d., a deal in which the Montvale, N.J., generic drug manufacturer topped a bid from Iceland's Actavis Group hf.

Horowitz landed the client after working across from Barr in negotiations on a potential deal in 2005 that fell through. He tapped Oded Eran and Adam Klein at Goldfarb, Levy, Eran, Meiri, Tzafrir & Co. as Israeli counsel on the Teva deal.

Barr used Paul Donofrio, Matt Miller, Chris Seiter and Michael Brocka at Banc of America Securities LLC

the company's longtime banker and its financial adviser on the Pliva transaction.

Teva tapped Mark Shafir, Jason Fertig and Punit Mehta at Lehman Brothers Inc., where vice chairman Harvey Krueger helped begin trading of the Israeli generic drug company's American Depositary Receipts in the 1980s. Lehman also advised Teva on its $7.4 billion stock and cash acquisition of Miami rival Ivax Corp. in 2005 and its $3.4 billion purchase of Sicor Inc. in 2003.

Willkie Farr & Gallagher LLP's Peter Jakes and Jeffrey Hochman led Teva's outside legal team. Willkie has worked with Teva since the 1980s and handled the Ivax and Sicor deals. Teva is also using David Hashmall and Frederick Rein of Goodwin Procter LLP on intellectual property and their partner Jonathan Price on products liability; Kirkland & Ellis LLP's Jay Lefkowitz on antitrust and Food and Drug Administration matters; and Menachem Tulchinsky and Yaacov Michlin of Tulchinsky Stern Marciano Ben-Zur Cohen & Co. as Israeli counsel.